EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSMAUG00000011695
Gene Symbol: MAP2K2
4 Cross references
261 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSMAUG00000007590
Gene Symbol: MAP3K1
3 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSMAUG00000019237
Gene Symbol: MAP3K12
3 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSMAUG00000012001
Gene Symbol: MAP3K13
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSMAUG00000017994
Gene Symbol: MAP3K5
4 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSMAUG00000003774
Gene Symbol: MAP3K8
4 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSMAUG00000020034
Gene Symbol: MAP3K9
3 Cross references
194 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSMAUG00000017953
Gene Symbol: MAOA
4 Cross references
147 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSMAUG00000017384
Gene Symbol: MAOB
4 Cross references
328 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSMAUG00000006292
Gene Symbol: MGLL
1 Cross references
208 Possible Orthologues:

Multidrug Resistance Protein 2

Ensembl ID : ENSMAUG00000010546
Gene Symbol: LOC101833290
3 Cross references
148 Possible Orthologues:

Myeloid Cell Leukemia Sequence 1

Ensembl ID : ENSMAUG00000007430
Gene Symbol: MCL1
1 Cross references
237 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).